Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

8302	Companies
115121	Keywords
55446	Articles
62530	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 06/10/2024 at 08:16, 5 months 11 days ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier

Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
BRIEF

published on 06/07/2024 at 08:28, 5 months 14 days ago

Biophytis Announces Combined General Meeting on June 24, 2024

Shareholders Biophytis General Meeting Voting Agenda
REGULATED PRESS RELEASE

published on 06/07/2024 at 08:23, 5 months 14 days ago

Combined General Meeting of June 24, 2024
Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website

Shareholders Voting Combined General Meeting Biophytis SA CGM
BRIEF

published on 06/07/2024 at 07:44, 5 months 14 days ago

Biophytis Combined General Meeting scheduled for June 24, 2024

Shareholders Biophytis Paris General Assembly Vote
PRESS RELEASE

published on 06/07/2024 at 07:39, 5 months 14 days ago

Combined General Meeting of June 24, 2024
Biophytis to hold Combined General Meeting (CGM) on June 24, 2024 at Sorbonne Université. Shareholders urged to vote in advance. Company specializes in age-related disease therapeutics

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF

published on 05/14/2024 at 07:05, 6 months 7 days ago

Biophytis Unveils Phase 2 OBA Clinical Study Design in Obesity

Biophytis Obesity Treatment Clinical Trial BIO101 OBA Clinical Study
PRESS RELEASE

published on 05/14/2024 at 07:00, 6 months 7 days ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), targeting muscle preservation in patients with obesity undergoing weight loss treatment with GLP-1 RAs

Biophytis BIO101 Muscle Preservation Obesity Phase 2 OBA Clinical Study
REGULATED PRESS RELEASE

published on 05/14/2024 at 07:00, 6 months 7 days ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025

Biophytis BIO101 Obesity Phase 2 OBA Clinical Study Muscle Function
BRIEF

published on 04/29/2024 at 14:44, 6 months 22 days ago

Biophytis announces the deployment of its partnership strategy in the obesity sector

Strategic Partnerships Biophytis Pharmaceutical BIO101 Obesity
PRESS RELEASE

published on 04/29/2024 at 14:39, 6 months 22 days ago

Biophytis is deploying its partnership strategy in obesity
Biophytis announces the implementation of a dedicated partnership strategy in obesity, aiming to collaborate with global pharmaceutical companies for drug development and commercialization. CEO Stanislas Veillet emphasizes the importance of addressing the obesity medical challenge through partnerships

Biophytis Drug Development Obesity Partnership Strategy Pharmaceutical Companies

Accesswire

Published on 11/21/2024 at 22:05, 1 hour 22 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 1 hour 37 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 3 hours 12 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 3 hours 17 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 27 minutes ago

Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 4 hours 26 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 51 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 28 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 5 hours 35 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 5 hours 36 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 16 hours 29 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 4 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE